Page 197 - Comprehensive treatment of patients with glucocorticoid-dependent severe asthma

“Monitoring exhaled nitric oxide (FeNO) to tailor 2010 0.5 the lowest effective dose of oral corticosteroids
in severe asthma (MONOSA-Study)”, oral
presentation, ATS New Orleans
“Monitoring exhaled nitric oxide to tailor the 2010 0.5 lowest effective dose of oral corticosteroids in
severe asthma”, Press conference, New Orleans
“High levels of Fractional Exhaled Nitric Oxide 2009 0.5 (FeNO) in severe oral steroid-dependent asthma
are associated with eosinophilia and atopy”,
thematic poster, ERS
“Patterns of Daily Exhaled Nitric Oxide (FeNO) in 2009 0.5 Severe, Steroid-dependent Asthma”, thematic
poster, ATS San Diego
“Stability of Exhaled Nitric Oxide (FeNO) in 2008 0.5 patients with severe, steroid-dependent asthma”,
thematic poster, ERS, Berlin
“Exhaled nitric oxide (FeNO), Asthma Control 2008 0.5 Questionnaire (ACQ) and FEV1 are complementary
disease-markers in steroid-dependent asthma”,
thematic poster, ATS Toronto
“Internet-Based Personalized Self-Management 2008 0.5 Program to Taper Oral Steroids in Severe Asthma:
The Patient’s Perspective”, thematic poster, ATS
Toronto
“pH of exhaled breath condensate and asthma 2007 0.5 severity: Is it confounded by steroid treatment?”,
oral presentation, ATS San Francisco
Portfolio
195
A